



# Training Course Agenda

PDA 211 Quality and Compliance Management for Virtual Companies

## DAY 1

### 8:30 Welcome and Introduction

- A. Introductions and participant expectations for the program
- B. Fundamentals of Good Manufacturing Practice
  - a. What is GMP?
  - b. Purpose of GMP
  - c. Basis in law: US, Europe, Canada
  - d. Elements that apply to all virtual companies
  - e. Elements that depend on how operations are conducted: How to tell what applies to your company
- C. Data Integrity: What it is and why it is important to GMP
- D. Postmarketing reporting – small molecule drugs vs biologic drugs (FDA requirements)
- E. Pharmacovigilance – pre and postmarket – FDA and EMA differences
- F. Regulatory and business risks: The case for compliance
- G. Virtual company organizational structure and responsibility for QA/GMP
- H. Virtual company quality system structure and management
  - a. Policies, procedures, documentation management
  - b. Metrics and management review considerations
- I. Selection, qualification and monitoring of contractors
  - a. Initial due diligence – public information sources to gage compliance
  - b. Qualification of vendors
  - c. Quality agreements – determining and documenting responsibilities for GMP
  - d. Vendor audit program
- J. Day One Q&A and recap of progress meeting stated course expectations

### 16:00 End of Day 1



# Training Course Agenda

PDA 211 Quality and Compliance Management for Virtual Companies

## DAY 2

### 8:30 Recap Day 1 then Day 2 Content

- A. Regulatory Inspections
  - a. Purpose of an inspection
  - b. Reasons for inspections
  - c. Inspections at virtual company headquarters locations – purpose and scope
  - d. Inspections at CMOs and Contract Labs
  - e. GMP inspections versus Preapproval inspections – FDA
  - f. EMA inspections – contrast with FDA
  - g. Health Canada inspections
- B. Logistics for managing inspections at your location
  - a. Information sources about inspections on agency web sites: What you need and how to find it easily
  - b. Preparation for inspections
  - c. Overall process – ready room support
  - d. Receiving and hosting the inspectors
  - e. Providing documents
  - f. Answering questions
  - g. Interpersonal dos and don'ts for interacting with inspectors
  - h. Managing the exit discussion at the conclusion of the inspection
- C. Inspections at your contract organizations
  - a. Making sure your CMO and contract lab are “PAI ready”
  - b. Training employees to assure inspection readiness – pitfalls to make sure you avoid
  - c. Conducting mock inspections effectively
- D. Post-inspection communications with the inspecting agency
  - a. How to write an effective response
  - b. Common mistakes to avoid
  - c. Following up to ensure the response is satisfactory
  - d. When to request a meeting, and if granted, how best to handle it
- E. Enforcement considerations
  - a. FDA enforcement process – domestic and ex-US
  - b. EMA enforcement
  - c. Health Canada
- F. Final Q&A, discussion, and conclusion

### 16:00 End of Training Course